Evidence digest
The indexed literature on Tirzepatide includes human clinical or observational records (5 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Tirzepatide is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 5 studies indexed · 5 human · compound record
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Meta-analyses of GLP-1 receptor agonist trialsPubMed listing | Meta-analysis | Not recorded | — | Placeholder seed record. Pooled analyses of trials of approved GLP-1 receptor agonist products. Meta-analytic findings inherit the population and product of the trials they pool, and do not transfer to material obtained outside that supply chain. | Listing |
| Randomised controlled trials of tirzepatide, the approved medicinePubMed listing | Human — controlled trial | Not recorded | — | Placeholder seed record. Trial literature for the approved dual GIP/GLP-1 agonist product. As with semaglutide, the evidence attaches to the approved product rather than to research-grade powder of unverified identity. | Listing |
| Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityThe New England journal of medicine · 2024 | Human — controlled trial | Not recorded | — | Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled… | PMID 38912654 |
| Tirzepatide Once Weekly for the Treatment of ObesityThe New England journal of medicine · 2022 | Human — controlled trial | Not recorded | — | Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more a… | PMID 35658024 |
| Tirzepatide for Obesity Treatment and Diabetes PreventionThe New England journal of medicine · 2025 | Human — controlled trial | Not recorded | — | Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. We perfor… | PMID 39536238 |
Placeholder seed entry recording the source, not an event. The European Medicines Agency publishes decisions on marketing authorisation. Approval status matters to this index because it determines whether the substance in a research-grade vial has an approved counterpart at all — and therefore whether a published trial literature exists for a product that is not the one being sold.
Placeholder seed entry recording the source, not an event. Shortage status for approved GLP-1 products materially affects this market: when an approved product is listed as in shortage, compounding of that substance becomes permissible under conditions, and demand shifts toward alternative supply. Resolution of a shortage reverses that. PepIndex records status changes here because they move the whole category.
The FDA proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulk drug substances list, finding no clinical need for outsourcing facilities to compound them from bulk now that the GLP-1 shortages are resolved. If finalized, the exclusion would close the last routine legal pathway for large-scale compounded GLP-1s and further narrow the supply of non-branded semaglutide and tirzepatide. The FDA took comments on the proposal through mid-2026 and is reviewing them; a final determination had not been published as of this writing.
After a short reconsideration, the FDA reaffirmed that the tirzepatide shortage was over, again requiring compounders to wind down production of copies. As with semaglutide, removal from the shortage list removes the basis that permitted compounded tirzepatide, tightening the supply of versions sold outside the approved products.
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Polaris Peptides | 93.877% | 16 | profile → |
| Next Gen Peptides | 93.897% | 1 | profile → |
| PeptidePlugs | 89.790% | 3 | profile → |
| Hydro Research Peptides | 88.289% | 7 | profile → |
| Prime Peptides | 87.180% | 3 | profile → |
| American Peptides | 83.6100% | 5 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| ZC Labs | 79.384% | 2 | profile → |
| Ascension Peptides | 78.186% | 2 | profile → |
| Vertex Labs | 70.170% | 2 | profile → |
| Disguised Alpha | 69.150% | 0 | profile → |
| Evolve Peptides | 65.567% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.